clinical trial · NCT04231851
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
University of California, Irvine·phase2·active not recruiting·n = 30
Acute Myelogenous Leukemia (AML) Due to TherapyAcute Myeloid Leukemia With Myelodysplasia-Related ChangesGlasdegibCPX-351
brief summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.
started
Feb 19, 2020
primary completion
Jun 30, 2024
completion
Jun 30, 2027
last updated
Mar 6, 2026
official title
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol